These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 17543572)

  • 1. Molecular targeted therapies in breast cancer: where are we now?
    Widakowich C; de Azambuja E; Gil T; Cardoso F; Dinh P; Awada A; Piccart-Gebhart M
    Int J Biochem Cell Biol; 2007; 39(7-8):1375-87. PubMed ID: 17543572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel cytotoxic backbones and targeted therapies: recent data and ongoing clinical trials.
    Moulder SL
    Clin Breast Cancer; 2010 Sep; 10 Suppl 2():S30-40. PubMed ID: 20805063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
    Emens LA
    Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.
    Conte P; Guarneri V; Bengala C
    Clin Breast Cancer; 2007 Dec; 7(11):841-9. PubMed ID: 18269773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls.
    Brandes AA; Franceschi E; Tosoni A; Degli Esposti R
    Expert Rev Anticancer Ther; 2010 Feb; 10(2):179-84. PubMed ID: 20131994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Novel targeted drug therapies in breast cancer].
    Bono P; Joensuu H
    Duodecim; 2010; 126(10):1205-15. PubMed ID: 20597350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.
    Spector NL; Blackwell KL
    J Clin Oncol; 2009 Dec; 27(34):5838-47. PubMed ID: 19884552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lapatinib in breast cancer: clinical experiences and future perspectives.
    Giampaglia M; Chiuri VE; Tinelli A; De Laurentiis M; Silvestris N; Lorusso V
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S72-9. PubMed ID: 21129615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
    Cameron DA; Stein S
    Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of metastatic breast cancer: looking towards the future.
    Amar S; Roy V; Perez EA
    Breast Cancer Res Treat; 2009 Apr; 114(3):413-22. PubMed ID: 18465221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variability in hormone and growth factor receptor expression in primary versus recurrent, metastatic, and post-neoadjuvant breast carcinoma.
    Jabbour MN; Massad CY; Boulos FI
    Breast Cancer Res Treat; 2012 Aug; 135(1):29-37. PubMed ID: 22484731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical updates on EGFR/HER targeted agents in early-stage breast cancer.
    Macrinici V; Romond E
    Clin Breast Cancer; 2010; 10 Suppl 1():E38-46. PubMed ID: 20587406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapies for the treatment of breast cancer in the post-trastuzumab era.
    Petrelli F; Cabiddu M; Cazzaniga ME; Cremonesi M; Barni S
    Oncologist; 2008 Apr; 13(4):373-81. PubMed ID: 18448551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress in systemic adjuvant therapy of early-stage breast cancer.
    Gradishar WJ; O'Regan RM
    Int J Clin Oncol; 2003 Aug; 8(4):239-47. PubMed ID: 12955580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lapatinib in the treatment of breast cancer.
    Higa GM; Abraham J
    Expert Rev Anticancer Ther; 2007 Sep; 7(9):1183-92. PubMed ID: 17892419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab not for ductal carcinoma in situ?
    Nahleh Z; Namakydoust A; Bakkar R; Bishop J
    Anticancer Drugs; 2007 Nov; 18(10):1231-5. PubMed ID: 17893526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multidisciplinary approach to the management of breast cancer, part 2: therapeutic considerations.
    Pruthi S; Boughey JC; Brandt KR; Degnim AC; Dy GK; Goetz MP; Perez EA; Reynolds CA; Schomberg PJ; Ingle JN
    Mayo Clin Proc; 2007 Sep; 82(9):1131-40. PubMed ID: 17803883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer.
    Damasceno M
    Curr Opin Oncol; 2011 Apr; 23 Suppl():S3-9. PubMed ID: 21490481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2-positive early breast cancer and trastuzumab: a surgeon's perspective.
    Kulkarni S; Hicks DG
    Ann Surg Oncol; 2008 Jun; 15(6):1677-88. PubMed ID: 18398661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.